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A study involving the presentation of 192 Belgian or Finnish prescriptions in pharmacies in another 
member state was undertaken to assess whether, as envisaged by European Union law, prescriptions 
issued in one member state are recognized by pharmacists in another and to identify factors that 
influence such decisions. Results show important differences depending on the country where 
prescriptions are presented. Willingness to dispense was higher when prescriptions were written by 
INN and in English, as opposed to prescriptions written by brand in a national language.  
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The 2011 European Union (EU) Directive on the application of patients’ rights in cross-border 
healthcare requires that someone presenting a prescription issued in one member state should be 
able to have it issued in another, subject to any relevant national legislation.1  However, there is very 
little evidence on whether this works in practice. It is estimated that 17 % of pharmacists in the EU 
are confronted with a foreign prescriptions more than 5 times a month, with much variation among 
member states.2 Only one study, published in 20013, addressed this issue and it involved only 28 
pharmacy visits and prescriptions for a single, widely used, antibiotic. We describe the experience of 
presenting prescriptions from abroad in five EU member states.   
Methods  
Prescriptions issued in Belgium and Finland were presented to pharmacists in Belgium, Finland, 
Germany, Spain and the United Kingdom (UK) between October 2011 and February 2012.  These 
countries represent different types of health system and account for 41% of the EU27 population4.  
Clinical scenarios were developed for three chronic disorders5,6,7 (i.e. asthma, secondary prevention 
after myocardial infarction, and type II diabetes) and one acute condition (inhibition of lactation) that 
could realistically require care while abroad.  No potentially problematic/unsafe medicinal products, 
were included in our research (see web appendix for detailed methodology). 
Results 
All 48 prescriptions presented domestically as controls (in Belgium and Finland) were dispensed, 
compared with 56% (108) of the 192 foreign prescriptions in the five counties (p<0.001).  
The type of prescription influenced the willingness to dispense; pharmacists were willing to dispense 
71% of prescriptions written by molecule in English and only 42% of those written by brand in a local 
language (p<0,001). 
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Willingness to dispense also varied according to the country where prescriptions were presented 
(p<0,001) with pharmacists in the UK and Finland least likely to dispense (only 29% and 33% of 
foreign prescriptions dispensed respectively), and German, Belgian and Spanish pharmacists most 
likely (79%, 67% and 67% of foreign prescriptions dispensed respectively).  Location of pharmacy and 
patient condition made no difference. 
The main reasons given by pharmacists in Finland and the UK related to their understanding of 
national legislation, with most Finnish pharmacists correctly reporting that they are legally restricted 
from dispensing non-Nordic prescriptions. However, British pharmacists also believed that the law 
barred them from dispensing foreign prescriptions, even though they are not.  
Only four UK pharmacists unwilling to dispense gave reasons other than national legislation (i.e. 
product not in stock or not being sure about the dosages or strengths written on the prescription). 
In Finland only two pharmacists who refused gave reasons other than not being able to dispense 
non-Nordic prescriptions as their main reason: difficult to validate the prescription, INN name written 
on the form not understood. 
In the remaining countries, where willingness to dispense was higher, the main reason for not 
dispensing was their inability to recognize the product name written on the prescription, typically a 
country-specific brand name. Five pharmacists in these countries gave other reasons not to dispense, 
(i.e. inability to understand hand writing or a belief that foreign prescriptions could not be 
dispensed).  
The right molecule was dispensed in all cases but brands and pack sizes sometimes differed from the 
prescribed ones. Pharmacists performed checks in over half of the visits (53 %), the most common 
involved searching in specific national databases (67% of all checks), while the second most common 
check was to search in the internet (33% of all checks). Seventeen percent of the checks included 
phone calls or direct consultation with managers, peers or authorities and only 11% of checks 
included searches of formularies or guidance documents.  
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Pharmacists questioned the researcher in 65% of the visits.  Questions about the origin of the 
prescription were asked in over half (52%) of visits. Medical questions were less common (24% of 
visits). Pharmacists were slightly more likely to raise questions during visits in which prescriptions 
used brand names and were written in a national language.  
The practically unanimous recommendation given by pharmacists unwilling to dispense was to visit a 
local GP.  
Discussion 
Our research found that, although willingness to dispense varied greatly depending on the country 
where prescriptions were presented, over half of pharmacists were willing to dispense. Differences in 
national law and practices clearly split the countries into two groups, with Finland and the UK being 
less willing to dispense than Belgium, Germany and Spain. In our study, the main reasons not to 
dispense in Finland and the UK related to perceived or actual legislation. Once the Directive is 
implemented, such differences should disappear. Yet, clear guidelines on how pharmacists should 
respond to EU prescriptions will be necessary. 
Reasons for not dispensing in the remaining countries were primarily linked to the impossibility of 
identifying the correct product when pharmacists were presented with prescriptions using country-
specific brand names. This obstacle appears to be key to dispensing. One obvious solution is for 
prescriptions written in the EU to use INNs. In the short term, an internet-based European product 
database allowing pharmacists to compare product names and identify the correct molecules would 
be very helpful. The verification of the authenticity of the prescription or the prescriber did not 
appear to play any role in the decision whether to dispense the product. We should recognise that 
our scenarios were for common conditions with few risks so our results should not be generalised to 
more complex cases in which the safety of the patient could be put at risk. Clear guidelines on the 
format of EU prescriptions, their minimum content, validity period, what to do or who to contact 
when confronted with them or what sources to consult on product composition and prescriber 
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credentials would be helpful and likely to have an impact not just on the availability of medication for 
citizens travelling to other member states, but also the time required for pharmacists to check the 
necessary information to dispense. Including the contact details of the prescriber in the prescription 
would have several benefits, including authentication of the prescriber and identification of the 
product if marketed under a different brand name. 
The study was subject to geographical limitations. All visits were centred around one or two large 
cities. However, we have no reason to believe that the findings would differ if another region/area in 
the countries had been chosen. 
It is not possible to ascertain whether the responses obtained in Germany may have been affected by 
the high refusal rate to participate (see web appendix).  However, the authors of this study 
considered an ethical obligation to give the opportunity to pharmacists of refusing to take part in the 
study. 
The sample size, although much larger than in the one previous study, is also a limitation. 
Dosage differences between countries, although limited in our exercise, could be of greater 
importance in more dosage-dependent conditions.  
To conclude, although more than half of the “patients” would have received their medication, there 
is still a long way to go before the Directive can be effectively applied in practice by pharmacists in all 
EU countries. There is clearly room for improving the current situation by developing measures to 
facilitate the duty of the dispensers while safeguarding the safety of patients.  
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Table 1:  Pharmacist willingness to dispense foreign (EU) prescriptions 
DISPENSED* NOT DISPENSED TOTAL PRESENTED DISPENSED (%) NOT DISPENSED (%) P VALUE
Type of Pharmacy 0,565
Centre 36 28 64 56,25 43,75
Outskirts 33 31 64 51,56 48,44
Rural 31 33 64 48,44 51,56
Patient case 0,838
Asthma 29 19 48 60,42 39,58
Myocardial infarction 25 23 48 52,08 47,92
Diabetes 26 22 48 54,17 45,83
Breast feeding inhibition 28 20 48 58,33 41,67
Country of origin 0,771
Finnish** 55 41 96 57,29 42,71
Belgian** 53 43 96 55,21 44,79
Type of prescription 0,000
Brand in local language 40 56 96 41,67 58,33
INN in English 68 28 96 70,83 29,17
Country where presented 0,000
Belgium 16 8 24 66,67 33,33
England 14 34 48 29,17 70,83
Finland 8 16 24 33,33 66,67
Germany 38 10 48 79,17 20,83
Spain 32 16 48 66,67 33,33
TOTAL 108 84 192 56,25 43,75





• The authentication of the prescription and prescriber does not seem to be an important issue 
when foreign (EU) prescriptions refer to relatively safe medical products.  
• Willingness to dispense was higher when prescriptions were written as INN and in English, as 
opposed to prescriptions written by brand in another national language. There is a need for 
guidance on when and how to dispense such prescriptions.  
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